The abstract is read at the publisher; the summary is JClub's.
Afatinib and erlotinib disrupt the corneal epithelial tight junction barrier in human corneal epithelial cells and Wistar rat corneas, with afatinib causing stronger ZO-1/occludin disruption.
- Why it matters: EGFR inhibitor–associated ocular toxicity is common in cancer care, but the corneal barrier mechanism is unclear.
- What they did: HCE cells were treated with erlotinib (5 μM) or afatinib (1.65 μM) for 24–48 h, and Wistar rats received topical dosing of erlotinib (500 μM) or afatinib (100 μM) for 1–4 weeks; tight junction mRNA/protein, FITC-dextran permeability, and immunostaining were measured.
- The result: Both inhibitors caused tight junction dysregulation and increased FITC-dextran permeability, while afatinib more strongly disrupted ZO-1 and occludin in HCE cells and downregulated ZO-2, ZO-3, and occludin proteins in rat corneas.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.